
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Remove Blood and blood components filter Blood and blood components (0)
- Complementary medicines (7) Apply Complementary medicines filter
- Fees/Payments (1) Apply Fees/Payments filter
- Remove Import/Export filter Import/Export (1)
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Remove Medical devices safety filter Medical devices safety (1)
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- OTC medicines (12) Apply OTC medicines filter
- Remove Other therapeutic goods filter Other therapeutic goods (1)
- Prescription medicines (5) Apply Prescription medicines filter
- Scheduling (55) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Remove Therapeutic goods regulation filter Therapeutic goods regulation (2)
- (-) Remove Medical devices safety filter Medical devices safety
- (-) Remove Blood and blood components filter Blood and blood components
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Other therapeutic goods filter Other therapeutic goods
- (-) Remove Import/Export filter Import/Export
- (-) Remove Therapeutic goods regulation filter Therapeutic goods regulation
Proposed changes to the Permissible Ingredients Determination: Low-negligible risk changes 2021-22
Closed on 15 September 2021
Proposal for clarifying regulatory requirements for residual claims for disinfectants
Closed on 26 March 2021
IMDRF consultation: Proposed update to document on Post-Market Clinical Follow-Up Studies
Closed on 11 December 2020
Export of therapeutic goods from Australia
Closed on 3 February 2020
Changes to permissible ingredients - Low-negligible risk
Closed on 11 October 2019
Proposed clarification that goods are therapeutic goods - goods containing folate substances in certain circumstances
Closed on 18 September 2019
Options for the future regulation of 'low risk' products
Closed on 12 May 2017